Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer.
靶向代谢脆弱性：REV-ERB 激动剂 SR9009 可增强索拉非尼在肝癌中的疗效。
期刊:Cell Death Discovery
影响因子:7
doi:10.1038/s41420-026-02940-3
Sabbioni Silvia, Guerriero Paola, Shankaraiah Ram C, Masatti Laura, Michilli Angelo, Bassi Cristian, D'Abundo Lucilla, Moshiri Farzaneh, De Siena Bruno, Simoni Edi, Astolfi Laura, Gramantieri Laura, Roncarati Roberta, Elamin Bahaeldin K, Bonora Massimo, Pinton Paolo, Croce Carlo M, Negrini Massimo, Callegari Elisa
